Compare Humana Inc (HUM) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Okta, Inc. — how do they compare? Humana Inc trades at $373.38 (market cap $46.31B), while Okta, Inc. trades at $150.3 (market cap $26.20B). The key difference: Humana Inc is the larger of the two by market cap, and Humana Inc pays a 0.92% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| HUM | OKTA | |
|---|---|---|
Market Cap | $46.31B | $26.20B |
Sector | Health | Technology |
52-Week High | $409.42 | $154.62 |
52-Week Low | $163.67 | $62.93 |
Enterprise Value | $53.67B | $24.03B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
OKTA trades at $148.32, up 3.35% today, near its recent high of $157.00. The stock shows bullish momentum with consistent earnings beats, including Q1 2026 EPS of $0.91 versus $0.853 expected. Revenue growth is robust, rising from $1.3B in 2022 to $2.6B in 2025, with net income turning positive at $28M. Technical indicators signal bullish trends, while analyst consensus is strongly positive with 72.55% buy ratings.
Outlook is favorable due to strong cybersecurity demand and AI-driven product launches, but risks include high valuation (P/E of 107.48) and competition. Upside potential exists if earnings growth continues, with a consensus price target of $127.96 suggesting caution relative to current price. Investors should monitor Q2 2026 results on August 26, 2026, for confirmation of profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
